ABCC7 p.Phe494Asn
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 18463704
[PubMed]
Serohijos AW et al: "Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding."
No.
Sentence
Comment
168
The solubilizing F494N mutation, which is adjacent to Q493, has also been shown to partially correct the folding defect of CFTR-DF508 [23].
X
ABCC7 p.Phe494Asn 18463704:168:17
status: NEW
No.
Sentence
Comment
155
The N1*⌬F and N1*4D contains the same mutations as defined in a. N1*3S incorporates the F429S, F494N, and Q637R solubilization mutations.
X
ABCC7 p.Phe494Asn 19176754:155:102
status: NEW174 Five, remarkably, introducing three solubilization mutations (F429S, F494N, and Q637R) that were required to produce soluble, recombinant NBD1 in bacteria (Lewis et al., 2005), significantly increased the steady-state cell surface expression of the CD4Tl-N1*-3S at 37°C and suppressed the expression defect at 26°C (Figure 3, b and c).
X
ABCC7 p.Phe494Asn 19176754:174:69
status: NEW291 In support of this hypothesis, severalfold increase in the cell surface expression of CD4T-NBD1* was documented in the presence of those solubilization mutations (F429N, F494N, and Q637R) that were required for the recombinant NBD1 expression (Figure 3, b and c) (Lewis et al., 2005).
X
ABCC7 p.Phe494Asn 19176754:291:170
status: NEW293 Indeed, the F429N, F494N, and Q637R mutations thermodynamically stabilized the isolated NBD1 in the absence of domain-domain interactions as indicated by the elevated melting temperature of the recombinant NBD1*-3S relative to its wt counterpart (Rabeh, Mulvihille and Lukacs, unpublished observations).
X
ABCC7 p.Phe494Asn 19176754:293:19
status: NEW
PMID: 19927121
[PubMed]
Kanelis V et al: "NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR."
No.
Sentence
Comment
107
Significant conformational changes, apart from differences in the local surface properties at the mutation site, were not observed in the crystal structures of DF508 NBD1-RE (also containing F429S, F494N, and Q637A mutations required for protein solubility and crystallization) (Lewis et al, 2004, 2005) and of DF508 NBD1 lacking the RI and the RE (PDB code 2PZF).
X
ABCC7 p.Phe494Asn 19927121:107:198
status: NEW249 The additional mutations (F494N, Q637A or F429S, F494N, and Q637R) in the DF508 NBD1-RE construct required for protein solubility and crystallization (Lewis et al, 2005) also partially rescue the trafficking and gating defects of full-length DF508 CFTR, suggesting that the crystal structure of DF508 NBD1-RE may correspond to a partially corrected conformation (Pissarra et al, 2008).
X
ABCC7 p.Phe494Asn 19927121:249:26
status: NEWX
ABCC7 p.Phe494Asn 19927121:249:49
status: NEW250 It is noteworthy that the F429S mutation is in the RI and further promotes the revertant effect produced by the F494N/Q637 mutant (Pissarra et al, 2008).
X
ABCC7 p.Phe494Asn 19927121:250:112
status: NEW
PMID: 19944699
[PubMed]
Lewis HA et al: "Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry."
No.
Sentence
Comment
48
These constructs have two solubilizing mutations selected because they are sequence variations naturally present in more soluble NBD1 variants from other vertebrate species [F494N in the γ- phosphate switch from several fish species (unpublished results) and Q637R in the RE from mouse].5,37 One newly reported ΔF508 structure has only these two mutations (PDB ID 2BBT, construct hNBD1-2f- ΔF508, Rwork =23.2 and Rfree =29.5 at 2.30 Å), while the other has an additional F429S mutation in a disordered region of the RI (PDB ID 2BBT, construct hNBD1-3-ΔF508, Rwork =22.6 and Rfree =29.1 at 2.05 Å).
X
ABCC7 p.Phe494Asn 19944699:48:174
status: NEW305 Equivalent structural analyses conducted on the F494N, Q637R, and H667R solubilizing mutations are described in detail in sections ST13-14 in the Supplementary Information.
X
ABCC7 p.Phe494Asn 19944699:305:48
status: NEW
PMID: 20150177
[PubMed]
Atwell S et al: "Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant."
No.
Sentence
Comment
65
Human NBD1 proteins utilized Clone name Sequencea 2935c469 Ser-NBD1[387-646(D405-436)] 2935c472 Ser-NBD1[387-646(D405-436,DF508)] 2935c492 Ser-NBD1[375-646(D405-436)] 2935c382b Ser-NBD1[389-678(F429S,F494N,Q637R)] 2935c371c Ser-NBD1[389-678(F429S,F494N,Q637R, DF508)] a All of the NBD1 proteins start with a non-native serine preceding the NBD1 sequence.
X
ABCC7 p.Phe494Asn 20150177:65:200
status: NEWX
ABCC7 p.Phe494Asn 20150177:65:247
status: NEW114 Human NBD1 387-646(D405-436) is more stable and binds ATP tighter than non-truncated constructs Truncated and non-truncated NBD1 proteins were analyzed for their thermal unfolding properties: NBD1 387-646(D405-436) and NBD1 389-678[F429S,F494N,Q637R].
X
ABCC7 p.Phe494Asn 20150177:114:238
status: NEW138 (B) The same analysis was conducted with NBD1[389-678(F429S,F494N,Q637R)] proteins (2935c382 and 2935c371).
X
ABCC7 p.Phe494Asn 20150177:138:60
status: NEW249 Many of the solubilizing mutations developed for non-truncated NBD1 are in the RI or Q-loop cleft (F409L, F429S, F433L and F494N) and might function by reducing these interactions.
X
ABCC7 p.Phe494Asn 20150177:249:123
status: NEW
PMID: 20551307
[PubMed]
Da Paula AC et al: "Folding and rescue of a cystic fibrosis transmembrane conductance regulator trafficking mutant identified using human-murine chimeric proteins."
No.
Sentence
Comment
218
Single Channel Behavior of Processing Mutant K584E-CFTR-In previous research, we demonstrated that revertant (e.g. G550E-CFTR (24)) and solubilizing mutations (e.g. F429S/F494N/Q637R (13)) rescue defects in CFTR channel gating in addition to promoting the cell surface expression of F508del-CFTR.
X
ABCC7 p.Phe494Asn 20551307:218:171
status: NEW
PMID: 20687133
[PubMed]
Protasevich I et al: "Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1."
No.
Sentence
Comment
44
hNBD1 Nameb Termini / Mutationsc Tm d DTm ¼ Tm D508 - Tm wt ( C) PDB ID 1 hNBD1-D(RI,RE) 2935c46917 387-646[D405-436] 57.7 þ 0.2 2PZE 1 (F508del)hNBD1D (RI,RE) 2935c47217 387-646[D405-436, F508del] 51.5 þ 0.3 À6.2 þ 0.3 2PZF 2 387-646[D405-436, V510D] 60.2 þ 0.4 2 387-646[D405-436, V510D, F508del] 53.0 þ 0.1 À7.2 þ 0.4 3 387-646[D405-436, F494N, Q637R] 59.2 3 387-646[D405-436, F494N, Q637R, F508del] 52.8 À6.4 4 387-646[D405-436, G550E, R553Q, R555K] 61.7 4 387-646[D405-436, G550E, R553Q, R555K,F508del] 55.7 À6.0 5 387-678[D405-436] 58.1 5 387-678[D405-436, F508del] 51.7 À6.2 6 hNBDI-315 2935c38217 389-678[F429S, F494N, Q637R] 49.8 þ 0.3 6 hNBDI-3F508del15 2935c37117 389-678[F429S, F494N, Q637R, F508del] 43.6 þ 0.1 À6.3 þ 0.3 2BBS 7 389-678[F429S, F494N, L636E5, Q637R] 50.5 þ 0.2 7 389-678[F429S, F494N, L636E, Q637R, F508del] 44.9 À6.2 þ 0.2 a DSC conducted at 1 mg/mL protein.
X
ABCC7 p.Phe494Asn 20687133:44:387
status: NEWX
ABCC7 p.Phe494Asn 20687133:44:426
status: NEWX
ABCC7 p.Phe494Asn 20687133:44:681
status: NEWX
ABCC7 p.Phe494Asn 20687133:44:756
status: NEWX
ABCC7 p.Phe494Asn 20687133:44:838
status: NEWX
ABCC7 p.Phe494Asn 20687133:44:893
status: NEW61 The Teem suppressor triplet (pair 4)29 increases Tm by 4 , the V510D mutation (pair 2)30 by 2.5 , and F494N/ Q637R (pair 3) by 1.5 .
X
ABCC7 p.Phe494Asn 20687133:61:104
status: NEW
PMID: 20687163
[PubMed]
Wang C et al: "Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis."
No.
Sentence
Comment
28
Surprisingly, several of these solubilizing surface mutations in hNBD1, identified in a screen focused exclusively on the in vitro solubility of hNBD1, were shown to suppress the in vivo trafficking defect of F508del-CFTR more strongly than the best existing pharmacological agents.32,38 Notably, the mutated residues (e.g., F429S, F494N, and Q637R) are not in direct contact with F508 and do not appear to be allosterically coupled.18 A similar hydrophobic-to-hydrophilic substitution in the immediate vicinity of F508, the V510D mutation, also strongly suppresses the in vivo trafficking defect of F508del-CFTR.39,40 It was proposed that these substitutions could block adventitious chaperone interactions that prevent proper ER export.18 However, there is as yet no concrete evidence explaining the tight correlation between the effects of mutations on the in vitro solubility properties of hNBD1 and the in vivo trafficking properties of human CFTR.
X
ABCC7 p.Phe494Asn 20687163:28:333
status: NEW118 Solubilizing surface mutations need to be introduced into full-length hNBD1 to obtain sufficient material for biophysical studies.15 Supporting Information Figure S5 compares the behavior of matched full-length and D(RI,RE) constructs containing F429S, F494N, and Q637R mutations15 in the absence or presence of the F508del mutation.
X
ABCC7 p.Phe494Asn 20687163:118:253
status: NEW159 The denaturation of hNBD1-D(RI,RE)-F508del is compared to that of the same construct containing in addition the Teem suppressor triplet37 (left), V510D39 (center), or F494N/Q637R15 (right).
X
ABCC7 p.Phe494Asn 20687163:159:167
status: NEW160 F494N/Q637R mutations were identified in a screen for surface substitutions that improve the solubility of purified hNBD1 in vitro.15 This screen focused on replacement of hydrophobic residues with more hydrophilic residues present at equivalent sites in other vertebrate CFTR sequences.
X
ABCC7 p.Phe494Asn 20687163:160:0
status: NEW161 These mutations also show significant efficacy in suppressing the trafficking defect caused by the F508del mutation in vivo in tissue culture cells,32 although they are less effective that the Teem suppressors,37 the V510D mutation,39,40 or deletion of the RI.41 The Teem suppressor triplet (Fig. 4A-C), the V510D mutation (Fig. 4D-F), and the F494N/Q637R mutations (Fig. 4G-I) all stabilize hNBD1 against the initial unfolding transition, shifting its midpoint 0.25-0.50 M higher in urea concentration.
X
ABCC7 p.Phe494Asn 20687163:161:344
status: NEW162 The magnitude of the SLS increase following the initial unfolding transition is greatly reduced by the Teem suppressor triplet and the V510D mutation and significantly reduced by the F494N/Q637R mutations.
X
ABCC7 p.Phe494Asn 20687163:162:183
status: NEW168 First, the SLS data in Figure 4I demonstrate that the F494N/Q637R mutation pair in the F508del domain is unique in suppressing the self-association that occurs without an increase in trp fluorescence before the onset of the initial unfolding transition.
X
ABCC7 p.Phe494Asn 20687163:168:54
status: NEW170 Second, the F494N/Q637R mutation pair appears to decrease the secondary structure content in the partially unfolded intermediate formed by both the F508del (Fig. 4G) and F508 (Supporting Information Fig. S8G) domains, while the Teem suppressor triplet may increase the secondary structure content in this state just in the F508del domain (Fig. 4A).
X
ABCC7 p.Phe494Asn 20687163:170:12
status: NEW189 See Lewis et al.39 for a detailed description of the subdomain organization of hNBD1 and the stereochemical effects of the F508del mutation, the Teem suppressor mutation triplet,37 and the F494N/Q637R solubilizing mutations.15 reveals that hNBD1 unfolds via two sequential transitions which have similar spectroscopic and aggregation properties whether unfolding is driven by urea or by heat.
X
ABCC7 p.Phe494Asn 20687163:189:189
status: NEW200 The Teem suppressor triplet and the F494N mutation are located on the opposite face of the ABCa subdomain from the V510D mutation, which is adjacent to the F508del site, and crystallographic studies indicate that the direct stereochemical effects of these different mutations are likely to be unrelated.18 The influence of all of these mutations on the initial unfolding transition suggests that it involves a global change in ABCa subdomain conformation.
X
ABCC7 p.Phe494Asn 20687163:200:36
status: NEW
PMID: 21486785
[PubMed]
Jih KY et al: "The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR."
No.
Sentence
Comment
12
We found that both the PPi-induced locked-open time and the ATP/P-ATP ligand exchange time of F508-CFTR channels are dramatically shortened, suggesting that the F508 mutation destabilizes the full and partial NBD dimer states. We also tested if mutations that have been shown to improve trafficking of F508-CFTR, namely the solubilizing mutation F494N/Q637R and RI (deletion of the regulatory insertion), exert any effects on these newly identified functional defects associated with F508-CFTR.
X
ABCC7 p.Phe494Asn 21486785:12:346
status: NEW143 We introduced into F508-CFTR the 'solubilizing mutations` F494N/Q637R (Pissarra et al. 2008) and the regulatory insertion deletion ( RI, deletion of residues 404-435) (Aleksandrov et al. 2010) to test whether they have any effects on the F508-CFTR gating defects described above.
X
ABCC7 p.Phe494Asn 21486785:143:58
status: NEW145 As seen in Figs 5A and 6A, in either case, the current relaxation upon removal of ATP and PPi was significantly slower compared with that for WT-CFTR (F494N/Q637R-CFTR: τ = 86.14 ± 12.61s, n = 6; RI-CFTR: τ = 75.33 ± 14.36 s, n = 7).
X
ABCC7 p.Phe494Asn 21486785:145:151
status: NEW147 For ligand exchange experiments, these mutations also significantly prolong the second phase of current changes upon switching the ligand from ATP to P-ATP (F494N/Q637R-CFTR: τ = 76.41 ± 12.31 s, n = 6; RI-CFTR: τ = 81.78 ± 6.66 s, n = 7) (Figs 5A, 6A and 7).
X
ABCC7 p.Phe494Asn 21486785:147:157
status: NEW149 We found that although the locked-open time (F494N/Q637R/ F508-CFTR: τ = 5.95 ± 0.36 s, n = 8; RI/ F508-CFTR: τ =5.52 ± 0.45 s, n = 11) and ligand exchange time (F494N/Q637R/ F508-CFTR: τ=8.44 ± 1.3s, n=6; RI/ Figure 5.
X
ABCC7 p.Phe494Asn 21486785:149:45
status: NEWX
ABCC7 p.Phe494Asn 21486785:149:184
status: NEW150 Effects of 'solubilizing mutations`, F494N/Q637R, on WTand F508-CFTR channels A, representative current traces of F494N/Q637R-CFTR channels locked opened by 1 mM ATP and 2 mM PPi (left) and ATP/P-ATP ligand exchange (right).
X
ABCC7 p.Phe494Asn 21486785:150:37
status: NEWX
ABCC7 p.Phe494Asn 21486785:150:114
status: NEW151 B, representative current traces of F494N/Q637R/ F508-CFTR channels locked opened by 1 mM ATP and 2 mM PPi (left) and ATP/P-ATP ligand exchange (right).
X
ABCC7 p.Phe494Asn 21486785:151:36
status: NEW157 F508-CFTR: τ = 8.95 ± 1.75 s, n = 4) of F494N/ Q637R/ F508 and F508/ RI channels are prolonged (Figs 5B, 6B and 7), they are still much shorter than those of WT channels.
X
ABCC7 p.Phe494Asn 21486785:157:51
status: NEW159 Besides prolonging the PPi locked-open time and the ligand exchange time, F494N/Q637R/ F508 and F508/ RI have been previously shown to improve the function of F508-CFTR (Pissarra et al. 2008; Aleksandrov et al. 2010).
X
ABCC7 p.Phe494Asn 21486785:159:74
status: NEW161 To our surprise, we found that P-dATP still increases the current dramatically for both compound mutants: 6.96 ± 0.17-fold increase for RI/ F508-CFTR (n = 5), and 12.36 ± 1.21-fold increase for F494N/Q637R-CFTR (n = 8) (Fig. 8).
X
ABCC7 p.Phe494Asn 21486785:161:204
status: NEW165 sol: solubilizing mutation, F494N/Q637R.
X
ABCC7 p.Phe494Asn 21486785:165:28
status: NEW170 Since P-dATP does not alter single channel conductance (Miki et al. 2010), the increase in the macroscopic current induced by P-dATP in F494N/Q637R/ F508 and F508/ RI (12-and 7-fold, respectively) suggests that the Po of these mutant channels is still lower than that of WT channels when ATP is used as the ligand.
X
ABCC7 p.Phe494Asn 21486785:170:136
status: NEW191 Effect of P-dATP on F494N/Q637R/ F508-CFTR and RI/ F508-CFTR Representative current traces of F494N/Q637R/ F508-CFTR (A) and RI/ F508-CFTR (B) in the presence of 50 μM P-dATP.
X
ABCC7 p.Phe494Asn 21486785:191:20
status: NEWX
ABCC7 p.Phe494Asn 21486785:191:94
status: NEW192 C, current increase induced by P-dATP for F494N/Q637R/ F508-CFTR (n = 8) and RI/ F508-CFTR (n = 5).
X
ABCC7 p.Phe494Asn 21486785:192:42
status: NEW
PMID: 21594798
[PubMed]
Kanelis V et al: "NMR spectroscopy to study the dynamics and interactions of CFTR."
No.
Sentence
Comment
136
Alternatively, the protein can be modified to increase solubility by specific point mutations (F494N and to a lesser degree F429S and Q637R) without deleting the RI (46).
X
ABCC7 p.Phe494Asn 21594798:136:95
status: NEW140 Higher concentrations of glycerol and lower temperatures further stabilize the protein, but increase the viscosity of the solution, leading to Table 25.1 List of preferred CFTR constructs for NMR studies Construct Boundaries "Solubilizing" mutations mNBD1-RE 389-673 G550E, R553M, R555K hNBD1a 387-404, 437-646 None hNBD1-REa 387-404, 437-678 None hNBD1-RE 389-678 F494N hNBD1-RE 389-678 F429S, F494N, Q637R aThe RI (residues 405-436) have been deleted in these constructs.
X
ABCC7 p.Phe494Asn 21594798:140:367
status: NEWX
ABCC7 p.Phe494Asn 21594798:140:397
status: NEW
PMID: 21182301
[PubMed]
Loo TW et al: "The W232R suppressor mutation promotes maturation of a truncation mutant lacking both nucleotide-binding domains and restores interdomain assembly and activity of P-glycoprotein processing mutants."
No.
Sentence
Comment
121
Suppressor mutations can rescueΔF508-CFTRbya variety ofmechanisms.Examplesinclude removal of the ER retention signals (arginine-framed trafficking motif mutations; R29K, R516K, R555K, and R766K) (61, 62), introduction of a combination of CFTR suppressor mutations (F949/Q637R or F29S/F494N/Q637R) that increase solubility of NBD1(63),orintroductionofsuppressormutationssuchasV510D (TMD1) (64) and R1070W(TMD2) (65) that restore NBD1-TMD2 interactions.
X
ABCC7 p.Phe494Asn 21182301:121:290
status: NEW
PMID: 22038833
[PubMed]
Colas J et al: "Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect."
No.
Sentence
Comment
29
The first one shows experimentally that NBD1 destabilization occurs as a consequence of three solubilizing mutations, namely V510D, F494N and Q637R (21).
X
ABCC7 p.Phe494Asn 22038833:29:132
status: NEW
PMID: 22265408
[PubMed]
Rabeh WM et al: "Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function."
No.
Sentence
Comment
26
Both the R mutations (G550E, R553Q, and R555K) and S mutations (F409L, F429S, F433L, F494N, and H667R) could partially rescue the DF508 CFTR folding and functional defect (Lewis et al., 2005; Pissarra et al., 2008; Teem et al., 1993, 1996) and were assumed to stabilize the domain either alone or in combinations (1S, 3S, R, R1S, and R4S; see Figure 1B).
X
ABCC7 p.Phe494Asn 22265408:26:85
status: NEW
PMID: 22701530
[PubMed]
Coppinger JA et al: "A chaperone trap contributes to the onset of cystic fibrosis."
No.
Sentence
Comment
229
NBD1-WT(F494N)-TTEVVMENVTAFWEEGFGELFE- KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF- KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS- GRISFCSQNSWIMPGTIKENIIFGVSYDEYRYRSVIKACQ- LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK- DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK- TRILVTSKMEHLKKADKILILHEGSSYFYGTF- SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF- SLEGDAPVS.
X
ABCC7 p.Phe494Asn 22701530:229:8
status: NEW230 NBD1-DF508 (F494N)-TTEVVMENVTAFWEEGFGELFE- KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF- KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS- GRISFCSQNSWIMPGTIKENIIGVSYDEYRYRSVIKACQ- LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK- DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK- TRILVTSKMEHLKKADKILILHEGSSYFYGTF- SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF- SLEGDAPVS.
X
ABCC7 p.Phe494Asn 22701530:230:12
status: NEW233 NBD1-WT(F494N)-TTEVVMENVTAFWEEGFGELFE- KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF- KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS- GRISFCSQNSWIMPGTIKENIIFGVSYDEYRYRSVIKACQ- LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK- DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK- TRILVTSKMEHLKKADKILILHEGSSYFYGTF- SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF- SLEGDAPVS.
X
ABCC7 p.Phe494Asn 22701530:233:8
status: NEW234 NBD1-DF508 (F494N)-TTEVVMENVTAFWEEGFGELFE- KAKQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINF- KIERGQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHS- GRISFCSQNSWIMPGTIKENIIGVSYDEYRYRSVIKACQ- LEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYK- DADLYLLDSPFGYLDVLTEKEIFESCVCKLMANK- TRILVTSKMEHLKKADKILILHEGSSYFYGTF- SELQNLQPDFSSKLMGCDSFDQFSAERRNSILTETLHRF- SLEGDAPVS.
X
ABCC7 p.Phe494Asn 22701530:234:12
status: NEW
PMID: 18215773
[PubMed]
Pissarra LS et al: "Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation."
No.
Sentence
Comment
5
Although F508del-NBD1 shows only minor conformational changes relative to that of wild-type NBD1, additional mutations (F494N/Q637R or F429S/F494N/Q637R) were required for domain solubility and crystallization.
X
ABCC7 p.Phe494Asn 18215773:5:120
status: NEWX
ABCC7 p.Phe494Asn 18215773:5:141
status: NEW33 However, these new F508del-NBD1 crystal structures still required either two (F494N/Q637R; Protein Data Bank [PDB] ID code: 2BBT) or three (F429S/F494N/ Q637R; PDB ID code: 2BBS) additional mutations for domain solubility and, hence, crystal formation (Lewis, 2005).
X
ABCC7 p.Phe494Asn 18215773:33:78
status: NEWX
ABCC7 p.Phe494Asn 18215773:33:146
status: NEW35 To test these ideas, we investigated the effects of the mutations F494N/Q637R and F429S/F494N/Q637R on wt- and F508del-CFTR by studying: (1) the in vivo folding yield of NBD1, (2) the processing and trafficking of the full-length CFTR protein, and (3) the ClÀ channel function of CFTR.
X
ABCC7 p.Phe494Asn 18215773:35:66
status: NEWX
ABCC7 p.Phe494Asn 18215773:35:88
status: NEW37 RESULTS While studying the effects of F508del on the structure of NBD1 from CFTR, Lewis (2005) introduced the mutations F494N/ Q637R (double; D) and F429S/F494N/Q637R (triple; T) into NBD1 to improve domain solubility and crystallization.
X
ABCC7 p.Phe494Asn 18215773:37:120
status: NEWX
ABCC7 p.Phe494Asn 18215773:37:155
status: NEW42 Solubilizing Mutations Improve wt- and F508del-NBD1 Yield To explore whether F429S, F494N, and Q637R improve the yield of soluble NBD1, wt-NBD1 and F508del-NBD1 were expressed in bacterial cells in the absence and presence of the solubilizing mutations.
X
ABCC7 p.Phe494Asn 18215773:42:82
status: NEW144 Structural Implications An interesting aspect of the action of the solubilizing mutations (double, F494N/Q637R; triple, F429S/F494N/Q637R) is their remote location from that of F508.
X
ABCC7 p.Phe494Asn 18215773:144:99
status: NEWX
ABCC7 p.Phe494Asn 18215773:144:126
status: NEW146 However, the effect produced by F494N is not completely unexpected, as structural crosstalk between the side chain of the F508 residue (e.g., F508R) and the Q loop or g-phosphate switch (e.g., residues W496 and M498) has been previously shown to occur (Massiah et al., 1999).
X
ABCC7 p.Phe494Asn 18215773:146:32
status: NEW151 In support of this notion, our data indicate that Q637R, at least with one additional solubilizing mutation (F494N), might contribute to the increased solubility of F508del-NBD1 and to the partial rescue of F508del-CFTR trafficking and function.
X
ABCC7 p.Phe494Asn 18215773:151:109
status: NEW152 The third solubilizing mutation, F429S, further promotes the revertant effect produced by the double mutant (F494N/Q637R) on F508del-CFTR, as the triple mutant (F429S/F494N/Q637R) visibly increased maturation of F508del-CFTR as measured by the higher maturation yield at steady state of F508delT-CFTR compared with that of F508delD-CFTR (Figure 1C).
X
ABCC7 p.Phe494Asn 18215773:152:109
status: NEWX
ABCC7 p.Phe494Asn 18215773:152:167
status: NEW175 The available crystal structure of F508del-NBD1 was determined after the introduction of additional mutations (F494N/Q637R or F429S/ F494N/Q637R) to help domain solubilization and crystal formation.
X
ABCC7 p.Phe494Asn 18215773:175:111
status: NEWX
ABCC7 p.Phe494Asn 18215773:175:133
status: NEW182 Site-Directed Mutagenesis, Cells, and CFTR Expression To introduce the solubilizing mutations F494N/Q637R and F429S/F494N/ Q637R into wt- and F508del-CFTR cDNAs in the pNUT expression vector, we used the primers F429S, 50 -GGTGATGACAGCCTCTCCTTCAGTAATTTC TCA-30 ; F494N, 50 -CATTCTGTTCTCAGAATTCCTGGATTATGCCTGG-30 ; Q637R, 50 -GAACTCCAAAATCTAAGGCCAGACTTTAGCTC-30 and the QuikChange site-directed mutagenesis kit (Stratagene).
X
ABCC7 p.Phe494Asn 18215773:182:94
status: NEWX
ABCC7 p.Phe494Asn 18215773:182:116
status: NEWX
ABCC7 p.Phe494Asn 18215773:182:261
status: NEW187 Cell lines expressing different solubilizing mutations are referred to as follows: wtD-CFTR, F494N-Q637R-CFTR; F508delD-CFTR, F494N- F508del-Q637R-CFTR; wtT-CFTR, F429S-F494N-Q637R-CFTR; and F508delT-CFTR, F429S-F494N-F508del-Q637R-CFTR.
X
ABCC7 p.Phe494Asn 18215773:187:93
status: NEWX
ABCC7 p.Phe494Asn 18215773:187:126
status: NEWX
ABCC7 p.Phe494Asn 18215773:187:169
status: NEWX
ABCC7 p.Phe494Asn 18215773:187:212
status: NEW
No.
Sentence
Comment
2
In this issue of Chemistry & Biology, Pissarra et al. (2008) show that partial rescue of the trafficking and gating defects of full-length CFTR occurs in vivo upon recapitulation of the solubilizing F494N/Q637R or F428S/F494N/Q637R substitutions in cis with F508 del.
X
ABCC7 p.Phe494Asn 18215767:2:199
status: NEWX
ABCC7 p.Phe494Asn 18215767:2:220
status: NEW19 Two F508 del-NBD1 structures lacking the suppressor mutations but retaining certain other alterations (F494N/Q637R or F428S/F494N/ Q637R) necessary for protein solubility subsequently became available (Lewis et al., 2005, http://www.pdb.org).
X
ABCC7 p.Phe494Asn 18215767:19:103
status: NEWX
ABCC7 p.Phe494Asn 18215767:19:124
status: NEW23 To address this question, Pissarra et al. (2008) report in this issue on the trafficking in mammalian cell lines of full-length CFTR proteins carrying wt, F508 del, or F508 del with the F494N/Q637R or F429S/F494N/ Q637R replacements.
X
ABCC7 p.Phe494Asn 18215767:23:186
status: NEWX
ABCC7 p.Phe494Asn 18215767:23:207
status: NEW25 Strikingly, the solubilizing mutations, notably the triple mutant F429S/ F494N/Q637R, appeared to promote some N-glycan processing in F508 del CFTR, to produce Band C, along with bands of MW intermediate between those of Band B and Band C, suggesting that these replacements partially rescue the trafficking defect.
X
ABCC7 p.Phe494Asn 18215767:25:73
status: NEW
PMID: 23055971
[PubMed]
Molinski S et al: "Functional Rescue of F508del-CFTR Using Small Molecule Correctors."
No.
Sentence
Comment
34
The first stabilizing mutations were identified in the ABC conserved, canonical subdomains, and cluster in the b1;-helical subdomain (G550R, R553Q, R555K), in the b3; switch (F494N), and ATP binding core subdomain (Q637R).
X
ABCC7 p.Phe494Asn 23055971:34:181
status: NEW
PMID: 23155000
[PubMed]
Ahner A et al: "Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway."
No.
Sentence
Comment
169
Purified NBD1 proteins containing a single suppressor mutation (1S, F494N) were incubated with or without purified components for 1 h at 27&#b0;C as illustrated and described in Materials and Methods.
X
ABCC7 p.Phe494Asn 23155000:169:68
status: NEW286 For cycloheximide chases, the culture medium was changed to one containing mutation, F494N, as previously described (Rabeh et al., 2012).
X
ABCC7 p.Phe494Asn 23155000:286:87
status: NEW
PMID: 23378596
[PubMed]
Hunt JF et al: "Cystic fibrosis transmembrane conductance regulator (ABCC7) structure."
No.
Sentence
Comment
165
The other mutation sets that improved the yield of soluble hNBD1 involved substitution of surface-exposed residues in hNBD1 with more polar residues occurring at the same position in CFTR orthologs from other species (F429S/F494N/ Q637R found in PDB ID 2BBS, F494N/ Q637R found in PDB ID 2BBT, and F429S/ H667R found in PDB ID 1XMI).
X
ABCC7 p.Phe494Asn 23378596:165:224
status: NEWX
ABCC7 p.Phe494Asn 23378596:165:259
status: NEW275 A series of second-site mutations in NBD1 have parallel effects in rescuing the trafficking defect in CFTR in vivo (DeCarvalho et al. 2002; Pissarra et al. 2008; Aleksandrov et al. 2010) and inhibiting molten globule formation by isolated NBD1 in vitro (G550E/R553Q/R555K, F494N/Q637R, or V510D) (Protasevich et al. 2010; Wang et al. 2010).
X
ABCC7 p.Phe494Asn 23378596:275:273
status: NEW
PMID: 23380248
[PubMed]
Hanrahan JW et al: "Novel pharmacological strategies to treat cystic fibrosis."
No.
Sentence
Comment
146
Conversely, pharmacological chaperones that restore the interface between NBD1 and MSD2 should be additive with the three solubilizing (3S) mutant in NBD1 (F494N, Q637R, F429S) [11].
X
ABCC7 p.Phe494Asn 23380248:146:156
status: NEW
PMID: 23865422
[PubMed]
Loo TW et al: "Bithiazole correctors rescue CFTR mutants by two different mechanisms."
No.
Sentence
Comment
24
It should be noted, however, that the ƊNBD2 CFTR used in this study was different from that used by Okiyoneda et al.18 The ƊNBD2 CFTR constructs in our study did not contain the G550E, R553Q, R555K, and F494N mutations or the three hemagglutinin tags in the fourth extracellular loop that could influence CFTR corrector interactions.
X
ABCC7 p.Phe494Asn 23865422:24:213
status: NEW
PMID: 23924900
[PubMed]
Ren HY et al: "VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1."
No.
Sentence
Comment
93
These mutations are termed solubilizing (S) mutations and were introduced into NBD1 in different combinations (Figure 5A, S2 [F429S, Q637R] and S3 [F429S, F494N, and Q637R]).
X
ABCC7 p.Phe494Asn 23924900:93:155
status: NEW178 S2 (F429S, Q637R) and S3 (F429S, F494N, and Q637R) are mutations introduced into NBD1 to increase the thermodynamic stability of NBD1 and thereby increase CFTR and F508del-CFTR (B and C) folding efficiency (Pissarra et al., 2008; Teem et al., 1993).
X
ABCC7 p.Phe494Asn 23924900:178:33
status: NEW184 %-Wt C-Band %-Wt C-Band C. F508 V510 R1070 ICL4 ICL2 F429 Q637 F494 NBD1 S2=F429S, Q637R S3=F429S, F494N Q637R FIGURE 4:ߒ Functional defects in CFTR caused by disease-related mutations in MSD1 are suppressed by VX-809.
X
ABCC7 p.Phe494Asn 23924900:184:99
status: NEW
PMID: 24058550
[PubMed]
Dawson JE et al: "Allosteric coupling between the intracellular coupling helix 4 and regulatory sites of the first nucleotide-binding domain of CFTR."
No.
Sentence
Comment
5
Titration of CL4 peptide into NBD1 perturbs the conformational ensemble in these sites with similar titration patterns observed in F508del, the major CF-causing mutant, and in suppressor mutants F494N, V510D and Q637R NBD1, as well as in a CL4-NBD1 fusion construct.
X
ABCC7 p.Phe494Asn 24058550:5:195
status: NEW25 The maturation defects can be partially suppressed by mutations in NBD1 or the CL4 coupling helix, such as V510D and F494N/Q637R [11,16-21], and by the drug VX-809 [22,23], now in clinical trials.
X
ABCC7 p.Phe494Asn 24058550:25:117
status: NEW27 Many of the F508del-suppressor mutations, such as F494N, as well as the RI deletion, increase the solubility of the NBD1 domain [20,24].
X
ABCC7 p.Phe494Asn 24058550:27:50
status: NEW29 Both the solubilizing double mutant F494N/Q637R and the deletion of the RI increase the locked open time of WT and F508del CFTR binding pyrophosphate [27].
X
ABCC7 p.Phe494Asn 24058550:29:36
status: NEW50 Similar titration patterns were observed in NBD1 constructs containing Q637R and mutations near the CL4-binding site (F508del, F494N, and V510D), as well as in a CL4-NBD1 fusion.
X
ABCC7 p.Phe494Asn 24058550:50:127
status: NEW56 Mutant NBD1 constructs with F494N, F508del, V510D, Q637R or F494N/ Q637R were constructed with a Stratagene QuikChange site-directed mutagenesis kit.
X
ABCC7 p.Phe494Asn 24058550:56:28
status: NEWX
ABCC7 p.Phe494Asn 24058550:56:60
status: NEW74 (The 1.0 mM F494N and F494N/Q637R NBD1 samples used 50 mM sodium phosphate to maintain consistent pH conditions.)
X
ABCC7 p.Phe494Asn 24058550:74:12
status: NEWX
ABCC7 p.Phe494Asn 24058550:74:22
status: NEW77 1.0 mM F494N and F494N/Q637R NBD1 samples were used for peak intensity comparison.
X
ABCC7 p.Phe494Asn 24058550:77:7
status: NEWX
ABCC7 p.Phe494Asn 24058550:77:17
status: NEW86 TROSY 15 N-1 H HSQC [40], T1 [41], and T1r [41] data were collected on 1 mM F494N, Q637R, and F494N/Q637R NBD1 samples using a cryoprobe-equipped 600 MHz Varian spectrometer.
X
ABCC7 p.Phe494Asn 24058550:86:76
status: NEWX
ABCC7 p.Phe494Asn 24058550:86:94
status: NEW115 Q637R is a solubilizing mutant that, in combination with F494N, partially corrects the folding defects induced by F508del in CFTR.
X
ABCC7 p.Phe494Asn 24058550:115:57
status: NEW121 The solubilizing mutation, F494N, reduces this association tendency.
X
ABCC7 p.Phe494Asn 24058550:121:27
status: NEW122 Both F494N NDB1 and F494N/Q637R NBD1 have a rotational correlation time of 2262 ns.
X
ABCC7 p.Phe494Asn 24058550:122:5
status: NEWX
ABCC7 p.Phe494Asn 24058550:122:20
status: NEW124 The experimental equivalence of F494N and F494N/Q637R NBD1 tc values reduces the probability that any difference in lineshape may be caused by a difference in association states.
X
ABCC7 p.Phe494Asn 24058550:124:32
status: NEWX
ABCC7 p.Phe494Asn 24058550:124:42
status: NEW125 Both decreases and increases in peak intensity, quantified by ratios of the intensities of the F494N/Q637R NBD1 and F494N NBD1 resonances (Figure 2B), are indicative of changes in dynamics.
X
ABCC7 p.Phe494Asn 24058550:125:95
status: NEWX
ABCC7 p.Phe494Asn 24058550:125:116
status: NEW127 y~ I(F494N Q637R) I(F494N) {1 &#f0;2&#de; These changes in intensity point to the Q637R mutation affecting the dynamics of F494N NBD1 in multiple locations.
X
ABCC7 p.Phe494Asn 24058550:127:5
status: NEWX
ABCC7 p.Phe494Asn 24058550:127:20
status: NEWX
ABCC7 p.Phe494Asn 24058550:127:139
status: NEW146 Overlay of F494N (black) and F494N/Q637R (orange) NBD1 HSQC spectra. B.
X
ABCC7 p.Phe494Asn 24058550:146:11
status: NEWX
ABCC7 p.Phe494Asn 24058550:146:29
status: NEW155 Q637R effects were probed using F494N NBD1 for improved solubility and spectral quality.
X
ABCC7 p.Phe494Asn 24058550:155:32
status: NEW175 CL4 also binds to NBD1 proteins containing single F508del-suppressor mutations, V510D and F494N, located near the predicted CL4-binding site, and Q637R, which lies between H8 and H9 (Figures 4 and S4).
X
ABCC7 p.Phe494Asn 24058550:175:90
status: NEW218 A, C, E, G. Dvobs between spectra of apo and CL4 peptide:NBD1 are shown in green for F508del, F494N, V510D, and Q637R NBD1, respectively.
X
ABCC7 p.Phe494Asn 24058550:218:94
status: NEW223 Dvobs values are mapped onto NBD1 structure as in Figure 2: B. F508del, D. F494N, F. V510D, and H. Q637R.
X
ABCC7 p.Phe494Asn 24058550:223:75
status: NEW224 F508del (position of F508 indicated as black sticks), F494N (orange space-filling representation), and V510D (purple space-filling representation) are near the predicted CL4-binding site.
X
ABCC7 p.Phe494Asn 24058550:224:54
status: NEW299 Chemical shift changes upon CL4 binding provide evidence for this allosteric network observed with minor variations in five variants of isolated NBD1-WT, F508del, F494N, V510D, and Q637R, in a CL4-NBD1 fusion protein with slightly different CL4 boundaries and in different buffer conditions.
X
ABCC7 p.Phe494Asn 24058550:299:163
status: NEW325 F508del suppressor modifications are found in this region as well, including the substitution of mouse RE into human CFTR [77] and Q637R, which in combination with F494N helps suppress folding defects in CFTR [20].
X
ABCC7 p.Phe494Asn 24058550:325:164
status: NEW338 Chemical shift changes in F494N NBD1 due to H8/H9 mutation Q637R limited to neighboring residues in S3/S9/S10 and H8/H9.
X
ABCC7 p.Phe494Asn 24058550:338:26
status: NEW339 The F494N mutation was used to improve solubility.
X
ABCC7 p.Phe494Asn 24058550:339:4
status: NEW357 Overlay of apo (black) and 12.5:1 CL4:NBD1 (red) spectra for A. F508del NBD1, B. F494N NBD1, C. V510D NBD1, and D. Q637R NBD1 mutants.
X
ABCC7 p.Phe494Asn 24058550:357:81
status: NEW
PMID: 24513531
[PubMed]
Moran O et al: "On the structural organization of the intracellular domains of CFTR."
No.
Sentence
Comment
1241
However, as the native preparation of NBD1 and NBD2 tend to precipitate at relatively low concentration (>2.5 mg/ml; Galeno et al., 2011; Galfr&#e8; et al., 2012), to obtain protein concentrations compatible with the crystallization conditions, three to seven revertant mutations (F409L, F429S, F433L, G550E, R553Q, R555K, H667R, Roxo-Rosa et al., 2006; F429S, F494N, Q637R, Pissarra et al., 2008) have been introduced into the NBD1.
X
ABCC7 p.Phe494Asn 24513531:1241:361
status: NEW
PMID: 24737137
[PubMed]
Phuan PW et al: "Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy."
No.
Sentence
Comment
43
The cloning and characterization of 3HA-tagged variants of ƊF508-CFTR, R1070W- ƊF508-CFTR, and 3S-ƊF508-CFTR (containing the F494N, Q637R, and F429S NBD1 suppressor mutations) were described (Okiyoneda et al., 2013).
X
ABCC7 p.Phe494Asn 24737137:43:140
status: NEW81 Isolation of recombinant human NBD1 containing a single suppressor mutation (1S; F494N) and melting temperature measurement were performed as described (Rabeh et al., 2012).
X
ABCC7 p.Phe494Asn 24737137:81:81
status: NEW101 Preferential correction of DF508-CFTR-3HA with the NBD1 stabilizing 3S mutations (F494N, Q637R, and F429S) compared with CFTR carrying the R1070W interface-stabilizing mutation has been taken as evidence that VX-809 preferentially stabilizes the interface between NBD1 and MSDs but not the NBD1 folding defect CFTR (Okiyoneda et al., 2013).
X
ABCC7 p.Phe494Asn 24737137:101:82
status: NEW
PMID: 25083918
[PubMed]
He L et al: "Restoration of NBD1 thermal stability is necessary and sufficient to correct F508 CFTR folding and assembly."
No.
Sentence
Comment
95
S492P or I539T alone slightly increased the Tm of NBD1 (ƊTm = 2-3 &#b0;C) similar to the affect of the solubilization mutations F494N and Q637R combined.
X
ABCC7 p.Phe494Asn 25083918:95:133
status: NEW
PMID: 26627831
[PubMed]
Ehrhardt A et al: "Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop."
No.
Sentence
Comment
48
This protein contained solubilizing mutations F494N/Q637R.
X
ABCC7 p.Phe494Asn 26627831:48:46
status: NEW
PMID: 26627832
[PubMed]
Gong X et al: "Non-native conformers of CFTR NBD1 are recognized by Hsp27 and conjugated to SUMO-2 for degradation."
No.
Sentence
Comment
61
Variants that contain a single solubilizing mutation, F494N, were used in most experiments; this mutation enhances the yield of both NBDs from bacterial expression.
X
ABCC7 p.Phe494Asn 26627832:61:54
status: NEW98 In vitro SUMOylation of NBD1 - WT or F508del NBD1 SUMOylation was performed in vitro using purified human 1S-NBD1, a variant containing a single solubilizing mutation (F494N) that was introduced into the NBD during crystallization trials (32).
X
ABCC7 p.Phe494Asn 26627832:98:168
status: NEW